DMECNCT05072262
DSAEK/DMEK and Cystoid Macular Edema - the Role for Topical NSAIDs (Nepafenac) (DMEC)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below.
- Minor Changed Registry marked status Unknown (sponsor has not verified the record since Nov 2022); last known: Recruiting
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of May 2022 to Nov 25, 2022
- Study sites: 0 to 1
- Notable Primary completion date: Jun 2023 to Jun 2024
- Start date: Oct 2021 to May 2022
- Study completion date: Oct 2025 to Oct 2026
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Central macular thickness after 4 weeks
Timeframe: 4 weeks after surgery
Cystoid macular edema (CME) after 4 weeks
Timeframe: 4 weeks after surgery
Secondary (7)
Intraocular inflammation
Intraocular pressure
Visual outcome
Corneal endothelial status
Patient reported outcome measure (PROM)
Show 2 moreShow less
Central macular thickness (CMT)
Cystoid macular edema (CME)
Arms and interventions
Control (dexamethasone only)Active comparator
Topical dexamethasone 1 mg/ml (Spersadex) started the day after surgery
Study group (NSAIDs and dexamethasone)Experimental
Topical nepafenac (Nevanac) 3 mg/ml and dexamethasone 1 mg/ml (Spersadex) started the day after surgery.
Drugs: Nepafenac Ophthalmic, Dexamethasone Ophthalmic
Sites
1 site in 1 country
- Department of Ophthalmology, Oslo University HospitalOslo, Norway